Stay updated on Novel Therapeutics for High-Risk AML Clinical Trial
Sign up to get notified when there's something new on the Novel Therapeutics for High-Risk AML Clinical Trial page.

Latest updates to the Novel Therapeutics for High-Risk AML Clinical Trial page
- Check5 days agoChange DetectedThe history adds entries for Contacts/Locations and Study Status on 2026-07-16, and an enrollment figure of 250 appears on 2026-07-15. These additions reflect updated administrative details and the trial's current status.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe latest version adds Contacts/Locations and Study Status to the version history, and updates the revision tag to v3.6.3. This reflects an enhanced display of historical attributes on the study record history page.SummaryDifference0.1%

- Check27 days agoChange DetectedA new revision entry (v3.6.2) was added to replace the previous v3.6.0, and the history now includes explicit labels for Contacts/Locations and Study Status in the version history.SummaryDifference0.2%

- Check34 days agoChange DetectedOn 2026-06-17, the record history gained new sections for Contacts/Locations and Study Status, enhancing visibility into who to contact and the trial's current status. The entry from 2026-06-11 was removed.SummaryDifference0.1%

- Check41 days agoChange DetectedThe latest revision adds a 'Check who can join' prompt, a 'Find Contact Information' option, and explicit 'Contacts/Locations' and 'Study Status' sections, and introduces the v3.6.0 revision label dated 2026-06-11 (replacing v3.5.5).SummaryDifference0.3%

- Check48 days agoChange DetectedVersion 2026-06-05 adds Contacts/Locations and Study Status to the record, accompanied by Revision: v3.5.5. This update changes how the study's contact information and current status are presented on the page.SummaryDifference0.2%

Stay in the know with updates to Novel Therapeutics for High-Risk AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Novel Therapeutics for High-Risk AML Clinical Trial page.